You just read:

Merck's Pembrolizumab Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

News provided by

Merck Canada Inc.

Dec 19, 2015, 10:55 ET